背景与目的:放射性脑损伤标志物的研究正在深入。本文探讨S100能否作为脑肿瘤对脑组织的损伤及脑肿瘤放射治疗中放射性脑损伤的生物学标志。方法:临床选择57例脑肿瘤患者,年龄17～69岁,平均46.7岁,男31例,女26例(其中行MRI检查30例,CT检查27例),所有患者经影像学或术后病理证实,其中脑胶质瘤20例,脑转移瘤21例,脑肿瘤单纯行放射治疗16例,所有患者且均行MRI或CT平扫及增强扫描,根据MRI、CT等影像结果测定肿瘤的最大径、肿瘤体积及判定瘤体周围水肿程度;同时抽取每位受检者静脉血3ml,分离血清,采用酶联免疫吸附法检测脑肿瘤患者及脑肿瘤单纯放疗结束后患者外周血中S100B蛋白水平。结果:放疗组患者外周血S100B蛋白含量明显高于脑胶质瘤组及脑MT组,分别(P<0.05)。正常组、脑MT组及脑胶质瘤组患者外周血S100B含量比较,差异无显著性(P>0.05)。肿瘤体积、最大径与血清S100B水平无线性相关,Ⅰ°和Ⅲ°水肿程度的血清S100B水平之间比较,差异有显著性(P=0.028)。结论:S100B蛋白不能作为脑胶质瘤与脑转移瘤的鉴别指标,可以作为脑肿瘤放射治疗导致放射性脑损伤的生物标志。 Background and Objective: The study of radioactive brain injury markers is under way. This article explores whether S100 can be used as a biological marker for brain tumor damage to brain tissue and radiation brain injury in brain tumors. Methods: Fifty-seven patients with brain tumor, aged from 17 to 69 years (average 46.7 years), including 31 males and 26 females (including 30 underwent MRI and 27 underwent CT). All patients underwent imaging or postoperative pathology Confirmed that there were 20 cases of glioma, brain metastases in 21 cases, brain tumor simple radiotherapy in 16 cases, all patients and underwent plain or enhanced MRI or CT scan, according to MRI, CT and other imaging results to determine the maximum tumor The volume of tumor, and the degree of edema around the tumor were determined. At the same time, 3ml venous blood was collected from each subject and the serum was separated. The levels of S100B protein in peripheral blood of patients with brain tumor and brain tumors were measured by enzyme-linked immunosorbent assay . Results: The level of S100B protein in peripheral blood of radiotherapy group was significantly higher than that of glioma group and MT group (P <0.05). The levels of S100B in the normal group, brain MT group and glioma group were not significantly different (P> 0.05). There was a significant difference (P = 0.028) between tumor volume and maximum diameter and serum S100B level, serum S100B level between Ⅰ ° and Ⅲ ° edema levels. Conclusion: S100B protein can not be used as a differential marker of brain gliomas and brain metastases, and can be used as a biomarker of radiation brain injury caused by radiation therapy in brain tumors.